Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00064211%3A_____%2F14%3A%230000392" target="_blank" >RIV/00064211:_____/14:#0000392 - isvavai.cz</a>

Výsledek na webu

<a href="http://dx.doi.org/10.1016/j.cllc.2014.04.007" target="_blank" >http://dx.doi.org/10.1016/j.cllc.2014.04.007</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1016/j.cllc.2014.04.007" target="_blank" >10.1016/j.cllc.2014.04.007</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)

Popis výsledku v původním jazyce

The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. NAVoTrial 01 is the first study that explores this combination specifically in nonsquamous (NS) NSCLC by assessing the feasibility of this doublet (ratio 1:2) in an investigational approach. A reference arm with pemetrexed plus cisplatin was included. Maintenance therapy with single-agent therapy after 4 cycles of combination therapy was included in the study schedules because it reflected a trend in first-line treatment of NSCLC.Patients and Methods Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m&sup2; and cisplatin 75 mg/m&sup2; on day 1 (arm A) or oral vinorelbine 80 mg/m&sup2; on days 1 and 8 (first cycle 60 mg/m&sup2;) and cisplatin 80 mg/m&sup2; on day 1 (arm B). After 4 cycles, patients without disease progression received single-a

Název v anglickém jazyce

Oral Vinorelbine Plus Cisplatin as First-Line Chemotherapy in Nonsquamous Non-Small-Cell Lung Cancer: Final Results of an International Randomized Phase II Study (NAVotrial 01)

Popis výsledku anglicky

The combination of oral vinorelbine plus cisplatin has been studied in numerous trials as first-line treatment of patients with non-small cell lung cancer (NSCLC) regardless of histologic subtype. NAVoTrial 01 is the first study that explores this combination specifically in nonsquamous (NS) NSCLC by assessing the feasibility of this doublet (ratio 1:2) in an investigational approach. A reference arm with pemetrexed plus cisplatin was included. Maintenance therapy with single-agent therapy after 4 cycles of combination therapy was included in the study schedules because it reflected a trend in first-line treatment of NSCLC.Patients and Methods Stage IIIB/IV untreated/relapsed patients with NS NSCLC received a 3-week cycle of pemetrexed 500 mg/m&sup2; and cisplatin 75 mg/m&sup2; on day 1 (arm A) or oral vinorelbine 80 mg/m&sup2; on days 1 and 8 (first cycle 60 mg/m&sup2;) and cisplatin 80 mg/m&sup2; on day 1 (arm B). After 4 cycles, patients without disease progression received single-a

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FF - ORL, oftalmologie, stomatologie

OECD FORD obor

—

Projekt

—

Návaznosti

I - Institucionalni podpora na dlouhodoby koncepcni rozvoj vyzkumne organizace

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

Clinical Lung Cancer

ISSN

1525-7304

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

4

Stát vydavatele periodika

IE - Irsko

Počet stran výsledku

8

Strana od-do

258-265

Kód UT WoS článku

000338412800002

EID výsledku v databázi Scopus

—